Category Archives: Editors Choice

The complex course of NF1 unraveled from different perspectives. Using clinical data, hereditary factors and biomarkers, we develop a personal risk profile for people with NF1-related plexiform neurofibromas for tailor-made treatment advice.

With a combination of clinical, genetic and biological information, we predict how benign and malignant tumors develop in people with NF1. This helps to improve treatments and follow-up in the future. The strength of the research lies in setting up a national system where all information about NF1 patients will be entered and stored (a database), including the storage of tissue material, which will be secured after an intervention or operation (a biobank).

We are still looking for a PhD candidate on this project. Check the vacancy page for more information.

Principal investigators: Rianne Oostenbrink/Walter Taal

On Friday 15 March, RTV Rijnmond joined Sabine Mous and Kamil Hiralal in the Sophia bus to see how we use it for research. The Sophia bus is an initiative from ENCORE scientists with the aim of reducing the pressure to participate in research.

The national network day NF1 expertise network took place on March 18 with the theme: Multidisciplinary network care for NF1.

Doesjka Hagenaar's research on the ROSA research has been published. We are pleased that everyone can now read it and would especially like to thank all participants. Doesjka's research focuses on finding suitable ways to measure the functioning of people with Angelman syndrome, with the aim of better measuring whether treatments work. If you would like to read the full publication, click here.

Background

Angelman syndrome (AS) is a rare neurological disorder characterized by intellectual disability, little to no expressive speech, visual and motor problems, behavioral problems, and a tendency to overeat and weight gain. The characteristics of AS make it difficult to measure the functioning of these children with standard clinical tests. Achievable outcome measures are needed to measure current functioning and change over time, both in clinical practice and clinical trials.

Goal

Our first goal is to assess the feasibility of different functional tests. We focus on the domain of neurocognitive functions and physical growth using the following measurement methods: eye-tracking, functional Near-Infrared Spectroscopy (fNIRS), indirect calorimetry, bioimpedance analysis (BIA), and BOD POD (air displacement plethysmography). Our second goal is to explore the results of the above measurements to better understand the AS phenotype.

Methods

The study population consisted of 28 children with AS aged 2-18 years. We defined an outcome measure as feasible when (1) at least 70% of participants successfully completed the measure and (2) at least 60% of those participants had acceptable data quality. Modifications to the testing procedure and reasons for early termination were noted. Parents rated feasibility and importance and were invited to make recommendations to increase feasibility. The results of the measurements were explored.

Results

Outcome measures obtained with eye-tracking and BOD POD met the definition of feasibility, while fNIRS, indirect calorimetry and BIA did not. The main reasons for early termination of measurements were signs of protest, inability to sit still and poor/no calibration (specifically for eye tracking). Post-calibration was often applied to obtain valid eye-tracking results. Parents rated the BOD POD as most acceptable and fNIRS as least acceptable for their child. All outcome measures were assessed as important. Exploratory results showed longer reaction times to highly salient visual stimuli (eye-tracking) as well as high body fat percentage (BOD POD).

Conclusions

Eye tracking and BOD POD are feasible measurement methods for children with AS. Eye tracking was successfully used to assess visual orientation functions in the current study and (with some practical modifications) can potentially be used to assess other outcomes as well. BOD POD was successfully used to investigate body composition.

Today is Rare Disease Day, a day when we want to raise awareness for people suffering from rare diseases. A group of people that is not that rare if you add everyone up. There are more than 300 million people worldwide with a rare disease.

On February 14 for a the ENCORE Expertise Center and ITHACA organize a symposium on genetic neurodevelopmental disorders.